TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6507770

Group type: EXPERIMENTAL
Intervention: Bupivacaine with initial peridural injection of 100 μg fentanyl
Number of subjects: 203

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 203
Study: 31659559

Group type: EXPERIMENTAL
Intervention: Traction device‐assisted ESD (group B)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional ESD (group A)
Number of subjects: 41
Study: 30122200

Group type: EXPERIMENTAL
Intervention: Test product containing hydrolyzed fish collagen, vitamins, antioxidants, and other active ingredients, taken daily for 90 days.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Test product
Number of subjects: 120
Study: 27858912

Group type: EXPERIMENTAL
Intervention: SOC + MVC (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SOC (n=9)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MVC intensification
Number of subjects: 20
Study: 25189855

Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 22473652

Group type: EXPERIMENTAL
Intervention: careHPV test
Number of subjects: 387
Study: 19835832

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Chloroquine plus Primaquine (CQ+PQ)
Number of subjects: 290
Study: 17324823

Group type: EXPERIMENTAL
Intervention: Focal medium-depth chemical peel (70% glycolic acid and 35% TCA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cryosurgery
Number of subjects: 25
Study: 16400485

Group type: EXPERIMENTAL
Intervention: Aciclovir and Prednisone (A+P group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Prednisone (P group)
Number of subjects: 46
Study: 11236211

Group type: EXPERIMENTAL
Intervention: Combination topical gel (5% benzoyl peroxide and 1% clindamycin)
Number of subjects: 159

Group type: COMPARATOR
Intervention: 1% clindamycin gel
Number of subjects: 159
Study: 9428832

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg daily
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg daily
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg daily
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Metformin 2000 mg daily
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Metformin 2500 mg daily
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study: 8484150

Group type: EXPERIMENTAL
Intervention: Exercise program during working hours to improve back muscle strength, endurance, and coordination
Number of subjects: 0

Group type: COMPARATOR
Intervention: No exercise program (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiotherapist intervention for training group
Number of subjects: 0
Study: 3303439

Group type: EXPERIMENTAL
Intervention: Azathioprine and low-dose prednisolone (AP)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cyclosporin (Cy)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: HLA-AB matching
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: HLA-DR matching
Number of subjects: 78
Study: 2526721

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA), 150 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 4602899

Group type: EXPERIMENTAL
Intervention: To‐336 vaccine
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: HPV77. DE‐5 vaccine
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: RA27/3 vaccine
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Cendehill vaccine
Number of subjects: 142
Study: 31400515

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modafinil for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy of CBT and modafinil for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy of CBT and modafinil
Number of subjects: 0
Study: 28203020

Group type: EXPERIMENTAL
Intervention: CFNB combined with PLIA (20 mL ropivacaine 5 g/L)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CFNB alone (normal saline)
Number of subjects: 100
Study: 26542509

Group type: EXPERIMENTAL
Intervention: 4-month supervised lifestyle intervention (exercise training, reduced sodium and calorie DASH eating plan, weight management)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standardized education and physician advice
Number of subjects: 150
Study: 22869047

Group type: EXPERIMENTAL
Intervention: Computer-based instructional strategies
Number of subjects: 995
Study: 21621331

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 45
Study: 19489935

Group type: EXPERIMENTAL
Intervention: Bone augmented with rhBMP-2 (test)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Bone augmented without rhBMP-2 (control)
Number of subjects: 11
Study: 16763334

Group type: EXPERIMENTAL
Intervention: IFN‐a2a (9 MU three times a week) and lamivudine (100 mg daily) for 12 months (Group 1)
Number of subjects: 68

Group type: COMPARATOR
Intervention: IFN‐a2a alone (9 MU three times a week) for 12 months (Group 2)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: IFN‐a2a and lamivudine (Group 1)
Number of subjects: 68

Group type: COMPARATOR
Intervention: IFN‐a2a alone (Group 2)
Number of subjects: 68
Study: 15622423

Group type: EXPERIMENTAL
Intervention: Individual ambulatory assistance
Number of subjects: 38

Group type: COMPARATOR
Intervention: Group educational program
Number of subjects: 38
Study: 11145797

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.03%
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.1%
Number of subjects: 985

Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 985
Study: 9024746

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (0.625 mg/day of Premarin)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8299660

Group type: EXPERIMENTAL
Intervention: Bambuterol 10 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bambuterol 20 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Terbutaline 5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Terbutaline 7.5 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bambuterol 10 mg vs Terbutaline 7.5 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bambuterol 10 mg vs Bambuterol 20 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bambuterol 20 mg vs Terbutaline high dose
Number of subjects: 40
Study: 3571318

Group type: EXPERIMENTAL
Intervention: Surgical treatment of ligamentous injuries
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-surgical treatment of ligamentous injuries
Number of subjects: 30
Study: 29084067

Group type: EXPERIMENTAL
Intervention: Coaching plus metronome
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Coaching plus visual feedback
Number of subjects: 70

Group type: COMPARATOR
Intervention: Coaching alone (control)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of male versus female
Number of subjects: 70
Study: 29784592

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) based care in an acute elderly care unit
Number of subjects: 408

Group type: COMPARATOR
Intervention: Usual medical care (control group)
Number of subjects: 408
Study: 26433763

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) in routine care
Number of subjects: 574

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) in RCTs
Number of subjects: 574
Study: 25551813

Group type: EXPERIMENTAL
Intervention: Combined sciatic-femoral nerve block with levobupivacaine 0.5% (40 ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spinal anaesthesia with 7.5 mg levobupivacaine 0.5%
Number of subjects: 40
Study: 22286203

Group type: EXPERIMENTAL
Intervention: aripiprazole 2 mg/day
Number of subjects: 225

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 225
Study: 20441798

Group type: EXPERIMENTAL
Intervention: Nicotine replacement
Number of subjects: 17
Study: 19126178

Group type: EXPERIMENTAL
Intervention: Nurse-led telemonitoring intervention
Number of subjects: 109

Group type: COMPARATOR
Intervention: Regular outpatient care (Control)
Number of subjects: 109
Study: 16330624

Group type: EXPERIMENTAL
Intervention: Systematic detection and multidisciplinary treatment of depression (consultation and treatment by a psychiatrist, follow-up by a research nurse and family physician)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 157
Study: 12698500

Group type: EXPERIMENTAL
Intervention: 250 mg bid of theophylline (Unilong)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 375 mg bid of theophylline (Unilong)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 37
Study: 10648261

Group type: EXPERIMENTAL
Intervention: 1 L unfiltered cafetière (French press) coffee daily for 2 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Water, milk, broth, tea, and chocolate drinks instead of coffee
Number of subjects: 64
Study: 9394654

Group type: EXPERIMENTAL
Intervention: i.v. contrast-enhanced spiral-CT
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: i.v. contrast-enhanced spiral-CT + spiral-CTAP
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: plain MR
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: plain MR + SPIO-enhanced MR
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: spiral-CTAP
Number of subjects: 35

Group type: COMPARATOR
Intervention: SPIO-enhanced MR
Number of subjects: 35
Study: 8282251

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg/day
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study: 3321397

Group type: EXPERIMENTAL
Intervention: Low-dose antacid treatment with additional ranitidine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Low-dose antacid treatment without ranitidine
Number of subjects: 56
Study: 30591198

Group type: EXPERIMENTAL
Intervention: Topical diltiazem applied three times a day
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 28931618

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (warfarin)
Number of subjects: 3623

Group type: EXPERIMENTAL
Intervention: Risk scores (HEMORR2HAGES, Shireman, HAS-BLED, ATRIA, ORBIT)
Number of subjects: 3623
Study: 26598477

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 22554354

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg day(‐1) for 4 days)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg day(‐1) for 6 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 22567069

Group type: EXPERIMENTAL
Intervention: Biofeedback-based stress management tool used three times daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with no specific intervention
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Biofeedback-based stress management tool during the 28-day extension period
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group during the 28-day extension period
Number of subjects: 40
Study: 18635021

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17075849

Group type: EXPERIMENTAL
Intervention: Acupuncture (up to 15 sessions in a 3-month period)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control (no acupuncture)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Acupuncture (nonrandomized group)
Number of subjects: 357
Study: 12930581

Group type: EXPERIMENTAL
Intervention: MIFT (tubal‐replaced microinjected oocytes)
Number of subjects: 63

Group type: COMPARATOR
Intervention: ICSI-embryo transfer (conventional day 2 embryo transfer)
Number of subjects: 63
Study: 10630736

Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg daily for 12 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Nitrendipine 20 mg daily for 12 weeks
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 96

Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 96
Study: 8852531

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 1531551

Group type: EXPERIMENTAL
Intervention: Back school program including information on back care, physical fitness, nutrition, stress, and relaxation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what intervention was received).
Number of subjects: 0
Study: 6391236

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 50 g of glucose added to porcine insulin (0.4 Ul.g-1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Glucose infusion without insulin
Number of subjects: 48
Study: 30854449

Group type: EXPERIMENTAL
Intervention: Multiparametric imaging biomarker for tumor hyperperfusion and hypercellularity (DCE-MRI and high b-value DW-MRI)
Number of subjects: 12
Study: 29351748

Group type: EXPERIMENTAL
Intervention: Medication (acetaminophen)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 119
Study: 26256457

Group type: EXPERIMENTAL
Intervention: Dementia initiative program implemented in 36 hospitals after identifying drawbacks in stage 1.
Number of subjects: 599214
Study: 24557758

Group type: EXPERIMENTAL
Intervention: Mydriasert (ophthalmic insert containing tropicamide and phenylephrine)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Eyedrops (tropicamide 1% and phenylephrine 10%)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Mydriasert and Eyedrops (both groups)
Number of subjects: 77
Study: 22089379

Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg twice/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 19515124

Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS (1 Hz, two trains of 500 pulses)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (sham coil)
Number of subjects: 27
Study: 17329700

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1
Study: 15237059

Group type: EXPERIMENTAL
Intervention: Color-coded method
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 101
Study: 12030642

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 0
Study: 9495425

Group type: EXPERIMENTAL
Intervention: Granisetron 2.5 mg (Group G)
Number of subjects: 150
Study: 8741025

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study: 2258249

Group type: EXPERIMENTAL
Intervention: SR nicardipine (40 mg b.i.d.)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg once daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7015846

Group type: EXPERIMENTAL
Intervention: Activated charcoal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31617468

Group type: EXPERIMENTAL
Intervention: Collaborative implementation intentions (IIs)
Number of subjects: 80
Study: 27830643

Group type: EXPERIMENTAL
Intervention: Simulator-based occupational therapy driving intervention (OT-DI); 3 sessions addressing driving errors and visual-search retraining
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traffic safety education (TSE); 3 sessions addressing personal factors and defensive driving
Number of subjects: 26
Study: 25330085

Group type: EXPERIMENTAL
Intervention: Short-graded protocol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Long-graded protocol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 20
Study: 24809482

Group type: COMPARATOR
Intervention: Group S (shallow block) with rocuronium 0.45 mg kg-1
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Group D (deep block) with rocuronium 0.6 mg kg-1
Number of subjects: 102

Group type: COMPARATOR
Intervention: Comparison of surgical field scores between groups S and D
Number of subjects: 102
Study: 23041997

Group type: EXPERIMENTAL
Intervention: Nano Foam cleaner
Number of subjects: 20

Group type: COMPARATOR
Intervention: ProFile File cleaner
Number of subjects: 20
Study: 20379032

Group type: EXPERIMENTAL
Intervention: Cold polymerized soft liner (Visco Gel)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Heat polymerized soft liner (Molloplast B)
Number of subjects: 32
Study: 17524123

Group type: EXPERIMENTAL
Intervention: New 4% hydroquinone cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial 4% hydroquinone creams
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4% hydroquinone product with 0.05% tretinoin and 0.01% fluocinolone acetonide
Number of subjects: 0
Study: 16253600

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/day (n = 48)
Number of subjects: 91

Group type: COMPARATOR
Intervention: no lipid-lowering treatment (n = 43)
Number of subjects: 91
Study: 11876795

Group type: EXPERIMENTAL
Intervention: 3 MU of IFN-alpha thrice weekly for 24 weeks
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Reinforced regimen for 48 weeks
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (nonresponders and relapsers)
Number of subjects: 165
Study: 10633742

Group type: EXPERIMENTAL
Intervention: Primary Nursing implemented in group 1 (two nursing units) after t1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary Nursing implemented in group 2 (three nursing units) after t2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-intervention period (t1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-intervention period (t2, 8 months after t1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-intervention period (t3, 14 months after t1)
Number of subjects: 0
Study: 7572740

Group type: EXPERIMENTAL
Intervention: high-linoleic acid margarine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: high-palm oil margarine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: high-palm oil margarine (interesterified)
Number of subjects: 27
Study: 1690551

Group type: EXPERIMENTAL
Intervention: Oral ribavirin 600 mg
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Oral ribavirin 800 mg
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 42523

Group type: EXPERIMENTAL
Intervention: 200 mg cimetidine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 200 mg cimetidine and 50 mg methanthelinebromide
Number of subjects: 17

Group type: COMPARATOR
Intervention: 50 mg methanthelinebromide
Number of subjects: 17
Study: 31416768

Group type: EXPERIMENTAL
Intervention: MTBVAC (5×10^5 CFU in 0.1 mL)
Number of subjects: 54

Group type: COMPARATOR
Intervention: BCG Vaccine SSI (5×10^5 CFU in 0.1 mL)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: MTBVAC (2.5×10^3 CFU in 0.05 mL)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: MTBVAC (2.5×10^4 CFU in 0.05 mL)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: MTBVAC (2.5×10^5 CFU in 0.05 mL)
Number of subjects: 54

Group type: COMPARATOR
Intervention: BCG Vaccine SSI (2.5×10^5 CFU in 0.05 mL)
Number of subjects: 54
Study: 28333185

Group type: EXPERIMENTAL
Intervention: Steiner-Tan Needle® flushing system (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Single-lumen aspiration needle (Gynetics®) (n = 40)
Number of subjects: 80
Study: 25771480

Group type: EXPERIMENTAL
Intervention: Static and dynamic orthoses
Number of subjects: 60

Group type: COMPARATOR
Intervention: Other hand therapy treatments (control)
Number of subjects: 60
Study: 22561230

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg once daily for 24 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Valsartan 80 mg once daily for 24 weeks
Number of subjects: 19
Study: 21739699

Group type: EXPERIMENTAL
Intervention: Acupotomy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 105

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 105
Study: 19608993

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Baseline antiplatelet use (single antiplatelet)
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Baseline antiplatelet use (double antiplatelet)
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Higher National Institutes of Health Stroke Scale score
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: CT changes defined by ASPECTS (ASPECTS < or =7)
Number of subjects: 965
Study: 16499476

Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg, orally, three times a day for 2 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (orally, three times a day for 2 days)
Number of subjects: 6
Study: 15005740

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Frusemide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Reversed osmosis water (control)
Number of subjects: 10
Study: 12521832

Group type: EXPERIMENTAL
Intervention: 17‐beta oestradiol 25‐mg vaginal tablets
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 9773136

Group type: EXPERIMENTAL
Intervention: Very slow injection of local anaesthetic (injection time 100 to 150 seconds, Group A)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Faster injection of local anaesthetic (injection time 40 to 80 seconds, Group B)
Number of subjects: 75
Study: 9623464

Group type: EXPERIMENTAL
Intervention: Computer-based learning package
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no access to computer material)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups (computer and control)
Number of subjects: 84
Study: 2923077

Group type: EXPERIMENTAL
Intervention: High P:S diet (P:S 1.0)
Number of subjects: 14
Study: 600190

Group type: EXPERIMENTAL
Intervention: Timolol (5 mg to 20 mg) with hydrochlorothiazide
Number of subjects: 65

Group type: COMPARATOR
Intervention: Hydrochlorothiazide alone
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Moduretic (hydrochlorothiazide, 50 mg and amiloride, 5 mg) with timolol
Number of subjects: 65

Group type: COMPARATOR
Intervention: Moduretic alone
Number of subjects: 65